Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Mar 29, 2017 20:12 pm UTC| Business
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Mar 29, 2017 20:11 pm UTC| Business
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Mar 29, 2017 20:11 pm UTC| Business
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Mar 29, 2017 20:11 pm UTC| Business
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Mar 29, 2017 20:11 pm UTC| Business
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 29, 2017 20:11 pm UTC| Business
SAN RAMON, Calif., March 29, 2017 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral...
SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 29, 2017 20:11 pm UTC| Business
SAN RAMON, Calif., March 29, 2017 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral...
US–India Trade Talks Race Toward USD 500 Billion Goal